Wird geladen...
Idelalisib —targeting PI3Kδ in patients with B cell malignancies
Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microen...
Gespeichert in:
| Veröffentlicht in: | Nat Rev Clin Oncol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4536758/ https://ncbi.nlm.nih.gov/pubmed/24642682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2014.42 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|